Latest Breaking News On - Flugen inc - Page 4 : comparemela.com

Share this article Share this article MADISON, Wis., May 25, 2021 /PRNewswire/  FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, today announced the initiation of the first study in older adults of M2SR, the company s investigational supra-seasonal, live, single-replication, intranasal influenza (flu) vaccine. Funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), this study will assess the safety, tolerability, and immunological response to M2SR in adults up to age 85, a population most vulnerable to serious complications and mortality from the flu. The study will evaluate subjects ability to raise antibodies against matched and drifted strains of the influenza virus. The extent to which all major components of the adaptive immune system are activated will also be measured. In a prior Phase 2 drifted H3N2 challenge trial, M2SR demonstrated effic

Carlos fierroPaul radspinnerNational institutes of healthNational institute of allergyFlugen incNational instituteInfectious diseasesNational institutesChief medical officerJohnson county clinical trialsPrincipal investigatorChief executive officerகார்லோஸ் பிர்றோதேசிய நிறுவனங்கள் ஆஃப் ஆரோக்கியம்தேசிய நிறுவனம் ஆஃப் ஒவ்வாமைதேசிய நிறுவனம்